The therapeutic landscape is rapidly evolving, with a wave of novel bioactives garnering significant attention . Among these cutting-edge compounds are Retatrutide, a dual GIP and GLP-1 receptor agonist showing https://tb-500189183.newsyblog.com/1727235/retatrutide-body-protection-compound-growth-factor-peptide-tb-a-deep-dive-into-emerging-bioactives